Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on May 17, 2022. The report discloses the entry into a material definitive agreement regarding a new equity financing facility.
Key Financial Metrics and Transaction Details
- Transaction Type: At-the-Market (ATM) Sales Agreement.
- Maximum Offering Amount: Up to $10,000,000 of common stock.
- Agent: Virtu Americas LLC.
- Commission: Up to 3.0% of gross proceeds.
- Financial Performance: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the authorization of a new mechanism to sell shares in the public market. The company has no obligation to sell any shares under this agreement and may suspend or terminate the offering at any time. The agreement will automatically terminate once the aggregate offering amount reaches $10,000,000.
Guidance, Outlook, and Risks
- Management Commentary: The company retains discretion over the timing and amount of share sales. The agent will use commercially reasonable efforts consistent with normal sales practices.
- Risks and Contingencies: The sale of shares is subject to market conditions and the terms of the Sales Agreement. The company has agreed to indemnify the agent against certain liabilities under the Securities Act of 1933.
- Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $10,000,000 offering.
- Review the full text of the ATM Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Confirm the status of the underlying shelf registration statement (Form S-3, File No. 333-251859).
- Check subsequent filings to determine if and when shares have actually been sold under this agreement.